Table 5.
Demographic and Clinical Characteristics of the Mode 2 Samples in the Optimization of ECT (OPT-ECT) Study
| Variable | Total Sample | 6 x ST RUL | 1.5 x ST BL | P-Value* | |
|---|---|---|---|---|---|
| Received Mode 1 | N | 319 | 155 | 164 | |
| Responders Mode 1 | N (%) | 163 (51.10) | 85 (54.84) | 78 (47.56) | 0.19 |
| Received Mode 2 | N (% eligible) | 59 (37.82) | 30 (42.86) | 29 (33.72) | 0.24 |
| Age | Mean±SD | 49.56±15.93 | 49.77±16.67 | 49.34±15.42 | 0.92 |
| Gender (female) | N (%) | 34 (57.63) | 19 (63.33) | 15 (51.72) | 0.37 |
| Education, yr | Mean±SD | 14.24±2.66 | 14.60±2.58 | 13.86±2.74 | 0.29 |
| PreECT HRSD | Mean±SD | 30.80±5.83 | 30.13±6.30 | 31.48±5.32 | 0.38 |
| PreECT BDI | Mean±SD | 38.56±9.02 | 39.12±8.88 | 38.38±9.98 | 0.78 |
| Bipolar Depression | N (%) | 13 (22.03) | 6 (20.00) | 7 (24.14) | 0.70 |
| Psychotic Depression | N (%) | 13 (22.03) | 8 (26.67) | 5 (17.24) | 0.38 |
| Length of Current Episode, mo † | Mean±SD | 14.26±17.91 | 15.53±16.19 | 12.89±19.79 | 0.58 |
| Total Number of Medication Trials§ | Mean±SD | 5.66±2.85 | 5.47±2.83 | 5.86±2.91 | 0.60 |
| Potency of “Best” Antidepressant Trial§ | Mean±SD | 3.27±1.17 | 3.20±1.13 | 3.35±1.23 | 0.65 |
| Medication Resistant§ | N (%) | 45 (76.27) | 23 (76.67) | 22 (75.86) | 0.94 |
| Number of Failed Adequate Trials§ | Mean±SD | 1.47±1.29 | 1.23±1.23 | 1.72±1.39 | 0.15 |
HRSD, Hamilton Rating Scale for Depression; BDI, Beck Depression Inventory,
*
P-values reflect results of independent t-tests or chi-square tests comparing the two Mode 1 randomized groups
†
Current episode duration was limited to 120 months;
§
Number of antidepressant medication trials, potency of each trial (scored 1= low, 5 = high), medication resistance categorization and number of failed adequate trials pertain to the current major depressive episode and were evaluated using the Antidepressant Treatment History Form (ATHF) [63]